Evidence map›Paper›PMID 21570499›Full record

ReviewJournal of proteomics2011

Proteomics and biomarkers in clinical trials for drug development.

Jung-min Lee, Jasmine J Han, Gary Altwerger, Elise C Kohn

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of proteomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 85 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Proteomics for cancer drug design.Expert review of proteomics · 2019
    Article
  13. Pharmaceutical Advances and Proteomics Researches.Iranian journal of pharmaceutical research : IJPR · 2019
    Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jung-min LeeMolecular Signaling Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892-1906, USA. leej6@mail.nih.gov
Jasmine J Han
Gary Altwerger
Elise C Kohn
National Cancer Institute · USCenter for Cancer Research · US

Funding

Signal Transduction Therapy--ClinicalZIASC009375 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI KOHN, ELISE C. · 2009 to 2013
$2.1M
The CCRWalter Reed Army Medical Center (WRAMC) Gynecologic Cancer Program ResearZIEBC011136 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOHN, ELISE C. · 2009 to 2013
$400k
Intramural NIH HHS Z99 CA999999NCI NIH HHS Y99 CA999999
6 · The paper itself

Abstract

Proteomics allows characterization of protein structure and function, protein-protein interactions, and peptide modifications. It has given us insight into the perturbations of signaling pathways within tumor cells and has improved the discovery of new therapeutic targets and possible indicators of response to and duration of therapy. The discovery, verification, and validation of novel biomarkers are critical in streamlining clinical development of targeted compounds, and directing rational treatments for patients whose tumors are dependent upon select signaling pathways. Studies are now underway in many diseases to examine the immune or inflammatory proteome, vascular proteome, cancer or disease proteome, and other subsets of the specific pathology microenvironment. Successful assay verification and biological validation of such biomarkers will speed development of potential agents to targetable dominant pathways and lead to selection of individuals most likely to benefit. Reconsideration of analytical and clinical trials methods for acquisition, examination, and translation of proteomics data must occur before we march further into future of drug development.

Indexed as

Drug DesignAnimalsAntineoplastic AgentsBiomarkers, TumorClinical Trials as TopicHumansNeoplasmsProteomicsSignal TransductionAntineoplastic AgentsBiomarkers, Tumor

Identifiers

PMID21570499
PMCPMC3158266
OpenAlexW1992059542

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.